For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announces AIRSUPRA® (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older.1 AIRSUPRA contains a short-acting beta2-agonist (SABA), to help relax the smooth muscles of the airways, and an inhaled corticosteroid (ICS), to he ...

In the latest trading session, Astrazeneca (AZN) closed at $66.54, marking a +0.03% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 1.23%. Elsewhere, the Dow saw an upswing of 1.06%, while the tech-heavy Nasdaq appreciated by 1.7%.Shares of the pharmaceutical witnessed a gain of 0.33% over the previous month, trailing the performance of the Medical sector with its gain of 3.16% and the S&P 500's gain of 0.94%.Analysts and investors alike will be keeping a close eye ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization. These results will be presented today at the 2024 American Society of Clinical Oncology Gastrointestinal ...

UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK is moved from 'sell' to 'buy,' while the investment bank's call on AZ moves in the opposite direction. Positivity over stock in GSK is underpinned by optimistic projections for Shingrix, its shingles vaccine. UBS anticipates Shingrix sales will outperform consensus expectations, driven by a new market opportunity i ...

Over 300 companies, including AstraZeneca, Anglo American, Endeavour Mining, Heathrow Airport and British American Tobacco, will start to include nature-related disclosures as part of their annual corporate reporting. Some of the early-adopter companies, which have a combined value of US$4 trillion, have committed to begin reporting on nature-related issues in their 2023 results, while others will start with their 2024 or 2025 results, it was announced as the agreement was formalised at the Davos summit tod ...

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca AZN, -2.82% AZN, +0.35% to sell from buy, while it upgraded GSK GSK, -0.44% GSK, +1.16% to buy from sell. It also upped Novartis NOVN, +0.25% NVS, -0.14% and Sanofi SAN, +0.03% SNY, -0.51% to buy from neutral, and Novo Nordisk NOVO.B, -0.19% NVS, -0.14% to neutral from sell.Analysts led by Matthew Weston say sector valuation ...

JP Morgan has maintained its bullish stance on AstraZeneca PLC (LSE:AZN) in the wake of the San Francisco healthcare conference it sponsors. Repeating its overweight stance £130 a share price target, the US bank provided its assessment of a Q&A session fronted by AZ's CFO Aradhana Sarin, which presented a robust outlook for the company. Sarin focused on the potential of the drug giant's pipeline, which includes the intention to launch 15 new therapies by the end of the decade. This prospective contribution ...

In the latest market close, Astrazeneca (AZN) reached $69.42, with a +0.35% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.02%.The pharmaceutical's stock has climbed by 4.27% in the past month, falling short of the Medical sector's gain of 6.57% and outpacing the S&P 500's gain of 3.52%.Analysts and investors alike will be keeping a close eye on the performance of Astrazene ...